# Endo T Monitoring Early And 6mo

> This skill recommends monitoring serum testosterone levels 3–6 weeks after initiating therapy and every 6 months thereafter to detect overuse or signs of androgen excess. It is triggered when a clinician manages a woman on testosterone therapy requiring early safety assessment and ongoing surveillance for adverse effects.

- Skill: `dromlakhani/endo-t-monitoring-early-and-6mo` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-t-monitoring-early-and-6mo`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-t-monitoring-early-and-6mo/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-t-monitoring-early-and-6mo

---


# Suggest testosterone monitoring at 3–6 weeks and every 6 months thereafter

## STEP 1 — Gather Information
Collect the date of testosterone therapy initiation, baseline testosterone level (if obtained), and any clinical signs of androgen excess such as acne, hirsutism, voice deepening, or clitoromegaly.

## STEP 2 — Rule In / Rule Out
Is the patient within 3–6 weeks of testosterone therapy initiation? If yes, proceed to early safety check; if no, proceed to routine 6‑month surveillance.

## STEP 3 — Classify or Stratify
Classify the measured testosterone level: elevated above the upper limit of the normal female range (suggesting overuse/androgen excess), within the normal range, or below the normal range (possible underdosing).

## STEP 4 — Decide
If testosterone is elevated, consider dose reduction or temporary discontinuation and re‑check in 3–6 weeks; if normal, continue current dose and repeat testing in 6 months; if low, evaluate for dose increase after assessing for lack of efficacy.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on symptoms alone for dose adjustment; avoid using immunoassays known to be inaccurate in women; do not continue therapy beyond 6 months without reassessment if there is no clinical response; do not use oral testosterone formulations formulated for men due to safety concerns in women.

## Concrete Clinical Example
A 52‑year‑woman with HSDD begins transdermal testosterone 300 µg/d. Baseline T is 12 ng/dL. At 5 weeks, T measures 48 ng/dL (above normal). The clinician reduces the dose to 150 µg/d and schedules a repeat level in 4 weeks.

**Source:** Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2260